8-K - Galera Therapeutics, Inc. | StockGist

Current Report Details

Event Type

Material Agreement

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

. Entry into a Material Definitive Agreement. As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “

Material Agreement

Biossil all of its dismutase mimetic assets, including the Company

Source Document

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Notice of Assignment to Blackstone Exhibit 104 Cover Page Interactive Data File

Exhibits Only

Exhibits (2)

10.1

EX-10.1

8-K